FUSION Blend – The Metabolic Stack

FUSION is the metabolic blend, and the only one where tesamorelin is at full strength. Tesamorelin sits at the highest concentration in the line, so it lands on the same doses used for tesamorelin on its own — with MOTS-c, 5-Amino-1MQ and BPC-157 alongside. 🔥 FUSION Blend — The Metabolic Stack No compromise on the headline compound. What it is, in plain English FUSION is the fat-loss and metabolism entry in the line. Most blends dilute their most important component; here tesamorelin is concentrated enough that the standard doses match what someone would take running tesamorelin alone. MOTS-c contributes on cellular energy, 5-Amino-1MQ is included for fat metabolism, and BPC-157 covers recovery. How it helps 🔥 Tesamorelin at full strength, studied for visceral fat ⚡ MOTS-c for mitochondrial energy 🧬 5-Amino-1MQ explored in fat metabolism research 💧 Arrives pre-mixed — nothing to reconstitute Why people reach for it Blends usually mean accepting a smaller dose of the compound that drew someone in. FUSION is the exception — the tesamorelin is not a token inclusion, which is why it is the one to look at for visceral fat specifically rather than general growth-hormone support. Tesamorelin alone FUSION Blend Tesamorelin dose Full The same Also included Nothing MOTS-c, 5-Amino-1MQ, BPC-157 Preparation Reconstitution required None — pre-mixed Is it a fit? FUSION suits someone focused on visceral fat and metabolic rate rather than growth hormone broadly. Take the 60-second peptide quiz or message our team, and our providers can point the way. 🔬 For the science-minded 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, studied in preclinical models of adipocyte metabolism. Tesamorelin is a GHRH analogue with clinical data in visceral adipose tissue reduction. MOTS-c is a mitochondrial-derived peptide. Growth-hormone-axis peptides affect blood sugar and are not appropriate for anyone with a personal history of cancer. Educational only — not medical advice. Peptides discussed here are research compounds; whether any is appropriate is a decision between a patient and their licensed provider.